07:01, 5 марта 2026РоссияЭксклюзив
All participants in the prescription drug supply chain deserve scrutiny, but weakening the mechanisms that extract price concessions will not lower drug spending. The more likely outcomes are gains for drug companies and less efficient pharmacies, and higher drug costs. Effects will be especially felt by seniors on Medicare and by smaller employers that lack the leverage to offset the law’s new constraints.
。关于这个话题，clash下载提供了深入分析
7-day free trial, then $59.99/month for 2 months
MIR provides solid gains while being the most portable backend
Последние новости